Physician profile
James C Barlow
NPI 1568465276
$2,458.03
in general payments reported to CMS, 2019-2025
16 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $276 · 2021: $435 · 2022: $343 · 2023: $276 · 2024: $355 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,311.25 | 2019-2025 | Viberzi, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.45 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $174.54 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $153.36 | 2019-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $120.47 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $96.07 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $64.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $50.16 | 2019-2020 | |
| Axonics, INC. | $49.49 | 2022-2024 | Axonics |
| Genzyme Corporation | $42.54 | 2024 | |
| Celltrion USA INC. | $28.53 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $27.14 | 2023 | |
| Boston Scientific Corporation | $17.58 | 2021 | |
| Aimmune Therapeutics, INC. | $17.32 | 2025 | Zenpep |
| Celgene Corporation | $16.24 | 2023 | Zeposia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $14.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.